p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing

Journal of Neurochemistry

Volumn 134, Issue 2, 2015, Pages 354-370

  Posada Duque, Rafael Andres ^a   López Tobón, Alejandro ^a   Piedrahita, Diego ^a   González Billault, Christian ^b   Cardona Gómez, Gloria Patricia ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

CDK5; neuroprotection; p35; Rho GTPases; RNAi

Indexed keywords

CYCLIN DEPENDENT KINASE 5; MICRORNA; PROTEIN P35; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; VIRUS VECTOR; NERVE PROTEIN; NEURONAL CDK5 ACTIVATOR (P25-P35); NEUROPEPTIDE; RAC1 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; RNA INTERFERENCE; SPATIAL LEARNING; SPATIAL MEMORY; ANIMAL; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING; WISTAR RAT;

ADENO-ASSOCIATED VIRUS; MUS;

ALZHEIMER DISEASE; ANIMALS; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NEUROPEPTIDES; RAC1 GTP-BINDING PROTEIN; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84936771130     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13127     Document Type: Article

References (84)

1. Bianchetta M. J., Lam T. T., Jones S. N., and, Morabito M. A., (2011) Cyclin-dependent kinase 5 regulates PSD-95 ubiquitination in neurons. J. Neurosci. 31, 12029-12035.
2. Bittner T., Fuhrmann M., Burgold S., Ochs S. M., Hoffmann N., Mitteregger G., Kretzschmar H., LaFerla F. M., and, Herms J., (2010) Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS ONE 5, e15477.
3. Bogush A., Pedrini S., Pelta-Heller J., Chan T., Yang Q., Mao Z., Sluzas E., Gieringer T., and, Ehrlich M. E., (2007) AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J. Biol. Chem. 282, 7352-7359.
4. Castro-Alvarez J. F., Gutierrez-Vargas J., Darnaudery M., and, Cardona-Gomez G. P., (2011) ROCK inhibition prevents tau hyperphosphorylation and p25/CDK5 increase after global cerebral ischemia. Behav. Neurosci. 125, 465-472.
5. Castro-Alvarez J. F., Uribe-Arias S. A., Kosik K. S., and, Cardona-Gomez G. P., (2014a) Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Front. Aging Neurosci. 6, 243.
6. Castro-Alvarez J. F., Uribe-Arias S. A., Mejia-Raigosa D., and, Cardona-Gomez G. P., (2014b) Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front. Aging Neurosci. 6, 232.
7. Castro-Alvarez J. F., Uribe-Arias S. A., and, Cardona-Gomez G. P., (2015) CDK5 targeting prevents β-amyloid aggregation involving GSK3 β and phosphatases. J. Neurosci. Res. In press.
8. Céspedes-Rubio A., Jurado F. W., and, Cardona-Gómez G. P., (2010) p120 catenin/αN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia. J. Neurosci. Res. 88, 3621-3634.
9. Cheung Z. H., Fu A. K., and, Ip N. Y., (2006) Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron 50, 13-18.
10. Cheung Z. H., Chin W. H., Chen Y., Ng Y. P., and, Ip N. Y., (2007) Cdk5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons. PLoS Biol. 5, e63.
11. Cruz J. C., Tseng H. C., Goldman J. A., Shih H., and, Tsai L. H., (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483.
12. Darios F., Muriel M.-P., Khondiker M. E., Brice A., and, Ruberg M., (2005) Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau. J. Neurosci. 25, 4159-4168.
13. Dhavan R., and, Tsai L.-H., (2001) A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759.
14. Fu A. K. Y., Fu W.-Y., Cheung J., Tsim K. W. K., Ip F. C. F., Wang J. H., and, Ip N. Y., (2001) Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat. Neurosci. 4, 374-381.
15. Govek E. E., Newey S. E., and, Van Aelst L., (2005) The role of the Rho GTPases in neuronal development. Genes Dev. 19, 1-49.
16. Gutiérrez-Vargas J. A., Castro-Álvarez J. F., Velásquez-Carvajal D., Montañez-Velásquez M. N., Céspedes-Rubio A., and, Cardona-Gómez G. P., (2010) Rac1 activity changes are associated with neuronal pathology and spatial memory long-term recovery after global cerebral ischemia. Neurochem. Int. 57, 762-773.
17. Hall A., (1998) Rho GTPases and the actin cytoskeleton. Science 279, 509-514.
18. Han P., Dou F., Li F., Zhang X., Zhang Y. W., Zheng H., Lipton S. A., Xu H., and, Liao F. F., (2005) Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J. Neurosci. 25, 11542-11552.
19. Harada T., Morooka T., Ogawa S., and, Nishida E., (2001) ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat. Cell Biol. 3, 453-459.
20. Harris L. L., Talian J. C., and, Zelenka P. S., (1992) Contrasting patterns of c-myc and N-myc expression in proliferating, quiescent, and differentiating cells of the embryonic chicken lens. Development 115, 813-820.
21. Hawasli A. H., Benavides D. R., Nguyen C., et al,. (2007) Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. 10, 880-886.
22. Hou Z., Li Q., He L., Lim H. Y., Fu X., Cheung N. S., Qi D. X., and, Qi R. Z., (2007) Microtubule association of the neuronal p35 activator of Cdk5. J. Biol. Chem. 282, 18666-18670.
23. Ittner L. M., Ke Y. D., Delerue F., et al,. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
24. Jaffe A. B., and, Hall A., (2005) Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269.
25. Jordan B. A., Fernholz B. D., Boussac M., Xu C., Grigorean G., Ziff E. B., and, Neubert T. A., (2004) Identification and verification of novel rodent postsynaptic density proteins. Mol. Cell Proteomics 3, 857-871.
26. Kerokoski P., Suuronen T., Salminen A., Soininen H., and, Pirttila¨ T., (2004) Both N-methyl-d-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci. Lett. 368, 181-185.
27. Kesavapany S., Amin N., Zheng Y.-L., et al,. (2004) p35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates rac-dependent extracellular signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule-associated protein 1b distribution in neurons. J. Neurosci. 24, 4421-4431.
28. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., and, Hisanaga S., (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275, 17166-17172.
29. Lee J.-H., and, Kim K.-T., (2004) Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells. J. Neurochem. 91, 634-647.
30. Leuba G., Savioz A., Vernay A., Carnal B., Kraftsik R., Tardif E., Riederer I., and, Riederer B. M., (2008a) Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J. Alzheimers Dis. 15, 139-151.
31. Leuba G., Walzer C., Vernay A., Carnal B., Kraftsik R., Piotton F., Marin P., Bouras C., and, Savioz A., (2008b) Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction. Neurobiol. Dis. 30, 408-419.
32. Leuba G., Vernay A., Kraftsik R., Tardif E., Riederer B. M., and, Savioz A., (2014) Pathological reorganization of NMDA receptors subunits and postsynaptic protein PSD-95 distribution in Alzheimer's disease. Curr. Alzheimer Res. 11, 86-96.
33. Lew J., Huang Q. Q., Qi Z., Winkfein R. J., Aebersold R., Hunt T., and, Wang J. H., (1994) A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423-426.
34. Li B. S., Sun M. K., Zhang L., Takahashi S., Ma W., Vinade L., Kulkarni A. B., Brady R. O., and, Pant H. C., (2001) Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc. Natl Acad. Sci. USA 98, 12742-12747.
35. Li B.-S., Ma W., Jaffe H., Zheng Y., Takahashi S., Zhang L., Kulkarni A. B., and, Pant H. C., (2003) Cyclin-dependent kinase-5 Is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem. 278, 35702-35709.
36. Linseman D. A., and, Loucks F. A., (2008) Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front Biosci. 13, 657-676.
37. Liu F., Su Y., Li B., Zhou Y., Ryder J., Gonzalez-DeWhitt P., May P. C., and, Ni B., (2003) Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 547, 193-196.
38. Lopes J. P., Oliveira C. R., and, Agostinho P., (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell. Mol. Neurobiol. 27, 943-957.
39. Ma T., Zhao Y., Kwak Y.-D., Yang Z., Thompson R., Luo Z., Xu H., and, Liao F.-F., (2009) Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J. Neurosci. 29, 11226-11236.
40. Mann D. M., Iwatsubo T., Cairns N. J., et al,. (1996) Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta 42(43). Ann. Neurol. 40, 149-156.
41. Morabito M. A., Sheng M., and, Tsai L. H., (2004) Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J. Neurosci. 24, 865-876.
42. Nguyen K. C., Rosales J. L., Barboza M., and, Lee K. Y., (2002) Controversies over p25 in Alzheimer's disease. J. Alzheimers Dis. 4, 123-126.
43. Nikolic M., Chou M. M., Lu W., Mayer B. J., and, Tsai L.-H., (1998) The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395, 194-198.
44. Noble W., Olm V., Takata K., et al,. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
45. Oddo S., Caccamo A., Shepherd J. D., et al,. (2003) Triple-transgenic model of Alzheimer's Disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
46. Ohshima T., Ogura H., Tomizawa K., et al,. (2005) Impairment of hippocampal long-term depression and defective spatial learning and memory in p35 mice. J. Neurochem. 94, 917-925.
47. Park K. H., Lu G., Fan J., Raymond L. A., and, Leavitt B. R., (2012) Decreasing levels of the cdk5 activators, p25 and p35, reduces excitotoxicity in striatal neurons. J. Huntingtons Dis., 1.
48. Patrick G. N., Zhou P., Kwon Y. T., Howley P. M., and, Tsai L.-H., (1998) p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway. J. Biol. Chem. 273, 24057-24064.
49. Patrick G. N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and, Tsai L. H., (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
50. Peng J., Kim M. J., Cheng D., Duong D. M., Gygi S. P., and, Sheng M., (2004) Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry. J. Biol. Chem. 279, 21003-21011.
51. Piedrahita D., Hernandez I., Lopez-Tobon A., et al,. (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J. Neurosci. 30, 13966-13976.
52. Plattner F., Hernandez A., Kistler T. M., et al,. (2014) Memory enhancement by targeting Cdk5 regulation of NR2B. Neuron 81, 1070-1083.
53. Posada-Duque R. A., Velasquez-Carvajal D., Eckert G. P., and, Cardona-Gomez G. P., (2013) Atorvastatin requires geranylgeranyl transferase-I and Rac1 activation to exert neuronal protection and induce plasticity. Neurochem. Int. 62, 433-445.
54. Putkonen N., Kukkonen J. P., Mudo G., Putula J., Belluardo N., Lindholm D., and, Korhonen L., (2011) Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus. Eur. J. Neurosci. 34, 1212-1221.
55. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
56. Read D. E., and, Gorman A. M., (2009) Involvement of Akt in neurite outgrowth. Cell. Mol. Life Sci. 66, 2975-2984.
57. Saito T., Konno T., Hosokawa T., Asada A., Ishiguro K., and, Hisanaga S., (2007) p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons. J. Neurochem. 102, 133-140.
58. Sananbenesi F., Fischer A., Wang X., Schrick C., Neve R., Radulovic J., and, Tsai L. H., (2007) A hippocampal Cdk5 pathway regulates extinction of contextual fear. Nat. Neurosci. 10, 1012-1019.
59. Semenova M. M., Maki-Hokkonen A. M., Cao J., Komarovski V., Forsberg K. M., Koistinaho M., Coffey E. T., and, Courtney M. J., (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat. Neurosci. 10, 436-443.
60. Shirao T., and, Gonzalez-Billault C., (2013) Actin filaments and microtubules in dendritic spines. J. Neurochem. 126, 155-164.
61. Shukla V., Zheng Y. L., Mishra S. K., Amin N. D., Steiner J., Grant P., Kesavapany S., and, Pant H. C., (2013) A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J. 27, 174-186.
62. Smith D. S., Greer P. L., and, Tsai L. H., (2001) Cdk5 on the brain. Cell Growth Differ. 12, 277-283.
63. Su S. C., and, Tsai L. H., (2011) Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol. 27, 465-491.
64. Tada T., and, Sheng M., (2006) Molecular mechanisms of dendritic spine morphogenesis. Curr. Opin. Neurobiol. 16, 95-101.
65. Takahashi S., Ohshima T., Cho A., et al,. (2005) Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc. Natl Acad. Sci. USA 102, 1737-1742.
66. Tanaka T., Veeranna, Ohshima T., et al,. (2001) Neuronal cyclin-dependent kinase 5 activity is critical for survival. J. Neurosci., 21, 550-558.
67. Timsit S., and, Menn B., (2012) Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke. Clin. Pharmacol. Ther. 91, 327-332.
68. Tokuoka H., Saito T., Yorifuji H., Wei F., Kishimoto T., and, Hisanaga S., (2000) Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J. Cell Sci. 113 (Pt 6), 1059-1068.
69. Trapp T., Olah L., Holker I., Besselmann M., Tiesler C., Maeda K., and, Hossmann K. A., (2001) GTPase RhoB: an early predictor of neuronal death after transient focal ischemia in mice. Mol. Cell Neurosci. 17, 883-894.
70. Trunova S., and, Giniger E., (2012) Absence of the Cdk5 activator p35 causes adult-onset neurodegeneration in the central brain of Drosophila. Dis. Model. Mech. 5, 210-219.
71. Tsai L.-H., Delalle I., Caviness V. S., Chae T., and, Harlow E., (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423.
72. Tsujita Y., Muraski J., Shiraishi I., Kato T., Kajstura J., Anversa P., and, Sussman M. A., (2006) Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl Acad. Sci. USA 103, 11946-11951.
73. Tymianski M., (2011) Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat. Neurosci. 14, 1369-1373.
74. Utreras E., Henriquez D., Contreras-Vallejos E., Olmos C., Di Genova A., Maass A., Kulkarni A. B., and, Gonzalez-Billault C., (2013) Cdk5 regulates Rap1 activity. Neurochem. Int. 62, 848-853.
75. Wang J., Liu S., Fu Y., Wang J. H., and, Lu Y., (2003) Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 6, 1039-1047.
76. Wang C. X., Song J. H., Song D. K., Yong V. W., Shuaib A., and, Hao C., (2005) Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2. Cell Death Differ. 13, 1203-1212.
77. Wei F. Y., Tomizawa K., Ohshima T., et al,. (2005) Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stability. J. Neurochem. 93, 502-512.
78. Zhang L., Liu W., Szumlinski K. K., and, Lew J., (2012) p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity. Proc. Natl Acad. Sci. USA 109, 20041-20046.
79. Zhang X., Hermandez I., Rei D., et al,. (2013) Diaminothiazoles modify tau phosphorylation and improve the tauopathy in mouse models. J. Biol. Chem., 30, 22042-22056.
80. Zheng Y. L., Kesavapany S., Gravell M., Hamilton R. S., Schubert M., Amin N., Albers W., Grant P., and, Pant H. C., (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24, 209-220.
81. Zheng Y. L., Li B. S., Kanungo J., Kesavapany S., Amin N., Grant P., and, Pant H. C., (2007) Cdk5 Modulation of mitogen-activated protein kinase signaling regulates neuronal survival. Mol. Biol. Cell 18, 404-413.
82. Zheng Y. L., Amin N. D., Hu Y. F., et al,. (2010) A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem. 285, 34202-34212.
83. Zhou Y., Su Y., Li B., et al,. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215-1217.
84. Zhu H., Bhattacharyya B. J., Lin H., and, Gomez C. M., (2011) Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J. Neurosci. 31, 15269-15283.